1st Annual BioPharma Obesity Innovation Forum

Building on the success of previous obesity panels and keynote in our Swiss events featuring many of the main players, we are pleased to introduce the 1st Annual BioPharma Obesity Innovation Forum (#Sachs_BOIF). This event will take place at the Marines’ Memorial Club, San Francisco on the 11th of January 2025, a day before the 8th Annual Neuroscience Innovation Forum (#Sachs_NIF). This new addition precedes the JP Morgan meeting, with the Virtual Week scheduled on the 21st – 23rd of January, offering relevant attendees the opportunity to register for both events.

We are witnessing a global obesity pandemic. By some estimates, a quarter of the world’s population will be obese by 2025. The obesity/weight loss drug market is the fastest-growing segment in the biopharma industry, with annual sales forecast to rise over $200 billion in the near term. Additionally, over 200 other conditions are associated with obesity. These include cardiometabolic diseases, cancer, inflammatory diseases, infertility, anxiety, depression, and kidney disease. This impacts the reimbursement case.

The comprehensive programme for the BOIF will feature over 7 hours of high-level keynotes, panel discussions, and corporate presentations covering all aspects of the bio-pharma obesity science and market, including drug development and technology, as well as highlighting investment opportunities. The sessions will be made available on demand for the virtual audience the week after the JP Morgan meeting. This forum will also set the stage for our first Obesity focused European event scheduled for the 17th – 19th of June 2025 in Leipzig. Key topics to be covered at the upcoming event include: